Some were concerned about increased imaging and interpretation times associated with DBT.
Adopting digital breast tomosynthesis (DBT) is not associated with a decrease in screening mammography capacity, according to a study published in the American Journal of Roentgenology.
Researchers from several states sought to determine whether adoption of DBT was associated with a decrease in screening mammography capacity across Breast Cancer Screening Consortium facilities, given concerns about increasing imaging and interpretation times associated with DBT.
The researchers collected facility characteristics and examination volume data from Breast Cancer Screening Consortium facilities that adopted DBT between 2011 and 2014. They evaluated differences between monthly screening volumes during the 12-month preadoption period and the 12-month postadoption period (with the two periods separated by a 3-month lag) and tested for changes in month-to-month facility-level screening volume during the preadoption and postadoption periods.
Related article: DBT Better Detects Cancer in Dense Breasts
The results showed that across five regional breast imaging registries, 15 of 83 facilities (18.1%) adopted DBT for screening between 2011 and 2014.
Facility-level monthly screening volumes were slightly higher during the postadoption versus preadoption periods. Monthly screening volumes remained relatively stable within the preadoption period and the postadoption period.
The researchers concluded that in a cohort of facilities with varied characteristics, monthly screening examination volumes did not decrease after DBT adoption.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.